期刊文献+

我院1220例药品不良反应报告分析 被引量:21

Analysis of 1 220 ADR Reports in Our Hospital
原文传递
导出
摘要 目的:探讨我院药品不良反应(ADR)工作存在的问题及持续改进措施。方法:对我院2009-2010年上报的1220例ADR报告,分别按患者年龄与性别、报告人职业、引起ADR的药品种类、临床表现、给药途径等方面进行回顾性统计、分析。结果:1220例ADR报告中,严重的和新的ADR76例(6.23%),医师和护士上报仅63例(5.16%),住院患者ADR发生率低(0.81%);抗微生物药引起的ADR最多,有574例(占47.05%);ADR临床表现以皮肤及其附件损害、消化系统反应等主观表现为主。结论:临床应完善医、药、护合作的ADR监测体系,提高医师和护士的上报比例;加强严重的、新的ADR监测,降低漏报率;结合科研采取合适的手段,发挥临床药师用药监护的作用,以减少可以预见的ADR发生。 OBJECTIVE:To investigate the problems and improvement measures of ADR monitoring in our hospital.METHODS:1 220 ADR reports collected from our hospital from 2009 to 2010 were analyzed retrospectively in respects of patient's age and gender,occupation of reporter,species of ADR-inducing drug,clinical manifestations,route of administration,etc.RESULTS:Among 1 220 ADR cases,there were 76 serious and new ADR cases(6.23%),only 63 cases were reported by doctors and nurses(5.16%).A small number of inpatients suffered from ADR(0.81%).574 cases were caused by antimicrobial drugs(47.05%).The clinical manifestations of ADR were based on subjective performance such as lesions of skin and its appendants and digestive system reaction.CONCLUSION:It is suggested that the doctor,pharmacist and nurse work together to improve the ADR monitoring system.We should increase the proportion of the ADR reported by the doctor and nurse.The serious and new ADR are strongly monitored.We must reduce the false negative rate of ADR.The appropriate measures with scientific research are adopted and the role of clinical pharmacist drug monitoring is played to reduce the incidence of ADR expected.
出处 《中国药房》 CAS CSCD 北大核心 2011年第38期3604-3607,共4页 China Pharmacy
关键词 药品不良反应 报告 分析 存在问题 Adverse drug reaction Report Analysis Existing problems
  • 相关文献

参考文献6

二级参考文献38

  • 1曾洁,何洁.福建省5053例药品不良反应报告分析[J].中国药物警戒,2006,3(5):283-285. 被引量:57
  • 2刘翎,臧熙,白玉国,张爱琴.124例中药制剂不良反应报告与分析[J].中国中药杂志,2006,31(22):1907-1908. 被引量:15
  • 3TENNIS P, STERN R S.Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study [J]. Neurology, 1997, 49(2): 542- 546.
  • 4CHUNG W H, HUNG S I, HONG H S, et al. Medical genetics: a marker for Stevens- Johnson syndrome [J]. Nature, 2004, 428(6982):486.
  • 5HUNG S I, CHUNG W H, JEE S H, et al. Genetic susceptibility to carbamazepine induced cutaneous adverse drug reactions [J]. Pharmacogenet Genomics, 2006, 16 (4) :297-306.
  • 6MAN C B, KWAN P, BAUM L, et al. Association between HLA-B*1502 allele and antiepileptic drug- Induced cutaneous reactions in Han Chinese [J]. Epilepsia, 2007,48(5): 1015- 1018.
  • 7LOCHARERNKUL C, LOPLUMLERT J, LIMOTAI C, et al. Carbamazepinf and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population [J]. Epilepsia, 2008,49(12):2087-2091.
  • 8LONJOU C, THOMAS L, BOROT N, et al.A marker for Stevens- Johnson syndrome: ethnicity matters [J]. Pharmacogenomics J, 2006, 6(4):265-268.
  • 9ALFIREVIC A, JORGENSEN A L, WILLIAMSON P R, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity [J]. Pharmacogenomics, 2006, 7 (6) :813-818.
  • 10KANIWA N, SAITO Y, AIHARA M, et al. HLA-B locus in Japanese patients with anti-ep ileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis [J]. Pharmacogenomics, 2008, 9(11):1617-1622.

共引文献82

同被引文献124

引证文献21

二级引证文献132

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部